Thousands of Norwegians mistakenly told they won big in European lottery game
Several thousand people were notified by Norsk Tipping that they had won "excessively high" Eurojackpot prizes on the evening of Friday, June 27.
Norsk Tipping said in a press release that the mistake was "made in the code that is entered into our game engine" when converting the sums from Euros to Norwegian kroner.
Norsk Tipping receives the prize amounts from Germany in Euros and later converts them to Norwegian kroner. Instead of the prize amounts being divided by 100, they were multiplied by 100.
"The incorrect prize amounts were removed from the website and app on Friday evening. The process of sending out prizes began at approximately 03:15, and was confirmed completed at approximately 04:30," Norsk Tipping said in a statement. "SMS and push notifications were sent to customers who have consented to receive such messages."
Fortunately for Norsk Tipping and unfortunately for those players, no customers were paid the wrong premium as a result of the error.
"Norsk Tipping sincerely apologizes to everyone who was notified of an incorrect prize amount," the Norwegian gambling company said.
Norsk Tipping CEO apologizes, steps down after 'manual error'
Tonje Sagstuen, former Norsk Tipping CEO, issued an apology to those who felt deceived, writing in a translated statement that she was "terribly sorry" to have disappointed so many and understood that people were angry.
"I have received many messages from people who had managed to make plans for holidays, buying an apartment or renovating before they realized that the amount was wrong," Sagstuen said in a statement. "To them I can only say: Sorry! But I understand that it is a small consolation."
The most recent incident was one of several serious errors uncovered by the company in recent months, according to Norsk Tipping. The "heavy criticism" from customers, the Norwegian Lottery Authority and the Minister of Culture as a result of those errors is "justified," Sagstuen said.
Sagstuen announced she would be stepping down as CEO a day after the news was made public. Sagstuen had worked at the company since 2014 and had been CEO since September 2023, the company told CBS News.
Vegar Strand, Director of Strategy, Analysis and Business Development, has taken the position of acting CEO in the interim.
Strand also issued a statement addressing and apologizing for the mishap, saying they were "now working intensively to ensure that this type of error does not happen again."
"On Friday evening, thousands of Norwegians were mistakenly told that they had won a large prize in Eurojackpot. This was an error that affected many and which we take very seriously," Strand said. "We deeply regret what has happened, and on behalf of us at Norsk Tipping I would like to apologize to everyone who was affected by this. We are incredibly sorry to have disappointed so many. "
Norsk Tipping added in the statement that it is "currently conducting a comprehensive review of all its systems to ensure that similar errors do not occur again."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
a day ago
- CNBC
London stock market could weather its biggest blow yet if AstraZeneca exits
Pressure is piling on London's stock exchange, with reports that British pharma giant AstraZeneca may move its listing to the U.S. delivering yet another blow this week. CEO Pascal Soriot is considering moving the company's stock listing from London to the U.S., British newspaper The Times reported on Tuesday afternoon, citing anonymous sources. Soriot's frustrations with the U.K.'s regulatory environment — particularly rules around new medicine approvals and drug pricing systems — are said to be driving the move. AstraZeneca declined to comment on the Times report. The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable business listed on London's FTSE 100. AstraZeneca's market cap was £161.2 billion ($221.1 billion) as of Tuesday's closing price, according to LSEG data. AstraZeneca's potential transatlantic move would add to concerns around London's weakening status as a global financial hub. A number of companies have delisted from the London market or reconsidered plans to float shares in the city over the past year. Toni Meadows, head of investment at London's BRI Wealth Management, labeled AstraZeneca's rumored listing considerations as "disappointing" for the U.K. equity market — but he conceded that "it is not surprising" given that it would form the latest development in a wider established trend. Earlier this year, reports emerged that Chinese fast fashion giant Shein was looking to list in Hong Kong instead of London, when it goes public. Last week, news agency Reuters reported that the company was planning to file confidentially for a Hong Kong IPO. Metals investor Cobalt Holdings, meanwhile, confirmed to CNBC last month that it had scrapped plans for a London IPO, while British fintech giant Wise announced in June that it was moving its primary listing from London to New York. Kristo Kaarmann, Wise's CEO and co-founder, said in a statement at the time that the move would help raise awareness of the company in the U.S., while giving the firm better access to "the world's deepest and most liquid capital market." Companies listed in London have historically had much lower valuations than their Wall Street counterparts. Research from British investment manager Rathbones last year showed that the forward price-to-earnings ratio for U.K. stocks was 32% lower than those listed in the U.S. on a like-for-like basis. On the flipside, the Financial Times reported last week that Norwegian software giant Visma had chosen London for its upcoming debut on the public market. "Large and important companies like AstraZeneca are seeking a valuation uplift from exposure to a wider investor base and they will get that from moving to a US listing," BRI's Meadows told CNBC via email on Wednesday. "The trend to move listing, or the stream of takeovers for UK listed stocks, highlights value in the UK equity market, but it does nothing to encourage a new supply of companies listing here to support the future standing of the index in a Global context," Meadows added. Claire Trachet, founder of M&A advisory Trachet, said AstraZeneca shifting its listing to New York would represent "a memorable loss" for the London Stock Exchange. "Given the complexity of the company, this isn't simply because of liquidity or valuation advantages often cited by departing firms, rather a trifecta of underperforming capital markets, regulatory constraints, and misaligned incentives that make it harder to scale and reward innovation at home," she told CNBC by email. Trachet added that London-listed companies with a combined value in excess of $100 billion had already made the move to New York in recent years — and AstraZeneca's departure alone would more than double that figure. "The potential move makes it painfully clear to global markets that the UK is losing its edge on the needs of world-class, scale-driven companies," she said. "This isn't an isolated story — and that's the biggest issue. It's part of a broader shift, where founders and boards are increasingly looking to the US for deeper capital, stronger support, and a more ambitious investor base." Tom Bacon, a London-based partner at global law firm BCLP — which has a division dedicated to M&A and corporate finance — labeled reports of AstraZeneca's Soriot's desire to shift away from London "very worrying." "I think this should sound the alarm for the UK government that they need to do more both to support the city and our stock market together with our critical industries like life sciences and pharmaceuticals," he said. Dan Coatsworth, investment analyst at AJ Bell, on Wednesday said that AstraZeneca's reported plans appeared to be driven by business needs rather than chasing a higher valuation — but he added that moving the company's listing across the Atlantic "won't be an easy move to pull off." "Unlike many other UK market 'defectors' with a dominant US shareholder base like CRH and Flutter, AstraZeneca has a more geographically diverse pool of investors," he explained in an email. However, Coatsworth noted that AstraZeneca generates around 42% of its sales from the U.S., and already has plans to increase its operational footprint in the country. Earlier this year, CEO Soriot told CNBC AstraZeneca was "very committed to the United States," where the company has two large research and development centers. AJ Bell's Coatsworth told CNBC that AstraZeneca's CEO could also see a full U.S. stock listing as a "stepping stone to receiving better treatment Stateside." European pharmaceutical companies are facing uncertainty around their future in the American market, where U.S. President Donald Trump has threatened to impose sector-specific tariffs on drug imports. While the industry was exempted from Trump's so-called reciprocal tariffs plans when they were unveiled in April, the White House leader has since placed the sector under investigation by the U.S. Commerce Department, warned tariffs on pharma are "coming soon," and signed an executive order directing medicine manufacturers to lower the price of some drugs in line with costs paid overseas.
UPI
2 days ago
- UPI
Thousands of Norwegians incorrectly informed of big lottery wins
A currency conversion error led to at least 47,000 people in Norway being incorrectly told that they had won big lottery prizes. File Photo by John Angelillo/UPI | License Photo July 1 (UPI) -- The national lottery operator in Norway apologized after at least 47,000 people who won small amounts were mistakenly told they had won much more. Norsk Tipping sent a text message to 47,000 lottery players in the country informing them that their reported prize amounts for the Eurojackpot drawing had been mistakenly inflated due to an error in currency conversion. The operator explained the prize amounts it receives from Germany are given in euros, which are then converted to Norwegian kroner. The error occurred during conversion for the recent Eurojackpot drawing, when the number of euros was multiplied by 100, instead of being divided. Ole Fredrik Sveen, 53, one of the players who received the correction, said he was initially told he had won 1.2 million kroner -- about $119,010 -- but later learned his prize was only 125 kroner, or $12.40. "You could have been really unlucky and spent a large amount of money then found out it wasn't true," Sveen told The Guardian. "But thankfully we kept our heads cool and realized it wasn't meant to be this time either." Norsk Tipping apologized for the error, saying none of the incorrect prize amounts had been paid out. "Norsk Tipping sincerely apologizes to everyone who was notified of an incorrect prize amount," the company said in a statement. Norsk Tipping CEO Tonje Sagstuen apologized in a separate statement issued Saturday. "I am terribly sorry that we have disappointed so many, and I understand that people are angry with us," Sagstuen said. "I have received many messages from people who had managed to make plans for holidays, buying an apartment or renovating before they realized that the amount was wrong." Sagstuen has since stepped down as CEO, and was replaced by acting CEO Vegar Strand. "We deeply regret what has happened, and on behalf of us at Norsk Tipping I would like to apologize to everyone who was affected by this," Strand said in a statement after taking up the position.
Yahoo
2 days ago
- Yahoo
Prospectus Approved for Listing of DNO's USD 600 Million Bonds on Oslo Stock Exchange
Oslo, 1 July 2025 – DNO ASA, the Norwegian oil and gas operator, today announced that the Financial Supervisory Authority of Norway on 1 July 2025 approved the prospectus prepared in connection with the listing on the Oslo Stock Exchange of the Company's 8.5 percent USD 600 million senior unsecured callable bonds issued on 27 March 2025 with maturity in March 2030 (ISIN: NO0013511113). Trading in the bonds is expected to commence shortly. The prospectus dated 1 July 2025 is available on the Company's website – For further information, please contact:Media: media@ – DNO ASA is a Norwegian oil and gas operator active in the Middle East, the North Sea and West Africa. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Côte d'Ivoire and Yemen. More information is available at This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. – This release does not constitute any offer or solicitation to sell or purchase any securities. The release may not be released, published or distributed in the United States of America or any other jurisdiction where release, publication or distribution would be prohibited or require any registration or filing acts or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
